

# OptiPrep™ Application Sheet V24

## Purification of Group V ((-)ss) RNA viruses: *Bunyaviridae* – *Hantavirus*, *Orthobunyavirus* and *Phlebovirus*

- ◆ OptiPrep™ is a 60% (w/v) solution of iodixanol in water, density = 1.32 g/ml
- ◆ This Application Sheet covers Bunyamwera virus (Section 2), Hantavirus (Section 3), and Rift Valley fever virus (Section 2).
- ◆ To access other Application Sheets referred to in the text return to the Virus Index; key Ctrl “F” and type the V-Number in the Find Box.
- ◆ For purification and analysis of other Group V ((-)ss) RNA viruses see OptiPrep™ Application Sheets V23 and V25-V28.

### 1. Background

There are now many published papers that report the use of iodixanol gradients not only to purify viruses but also to investigate their assembly. In all comparative studies between CsCl and iodixanol, the recovery of virus infectivity is much higher and the particle:infectivity ratio much lower when viruses are purified in iodixanol. Although sucrose is generally less deleterious to viral infectivity than CsCl, it can nevertheless also have serious effects on certain important aspects of viral function; in particular the loss of surface glycoproteins from retroviruses has been noted [1]. This may be related to its viscosity, which, in solutions of the same density, is much higher than that of iodixanol.

Like CsCl, sucrose must be dialyzed before infectivity can be measured. In contrast both infectivity measurements using cultured cells and many add-on techniques can be performed without dialysis of iodixanol. Combined with the availability of OptiPrep™ as a sterile solution, this makes the use of OptiPrep™ for virus purification and assembly analysis much more convenient than the use of either CsCl or sucrose.

Bunyamwera virus and Rift Valley fever virus (Section 2) have been purified in continuous gradients of iodixanol; Sin Nombre hantavirus (Section 3) in self-generated and pre-formed discontinuous iodixanol gradients. Whether a particular method can be applied to any –ve sense RNA virus can only be determined experimentally.

### 2. Analysis of Bunyamwera virus

The protocol is adapted from refs 2 and 3. [See Section 2d, Notes 1 and 6 re Rift Valley virus.](#)

#### 2a. Solutions required (see box ⇒)

- A. OptiPrep™
- B. OptiPrep™ Diluent: 0.2 M NaCl, 2 mM EDTA, 0.02 M Tris-HCl, pH 7.4
- C. Working solution (30% w/v iodixanol): Mix equal volumes of OptiPrep™ and Solution B.
- D. Buffer: 0.1 M NaCl, 1 mM EDTA, 0.01 M Tris-HCl, pH 7.4

Include protease inhibitors in Solutions B and D as required.

#### 2b. Rotor requirements

Swinging-bucket rotors with approx 13 ml tubes (e.g. Beckman SW41Ti) and approx 38 ml (e.g. Beckman SW28)

Prepare 100 ml of each of the following stock solutions and keep at 4°C:

100 mM Tris (free base)	1.21 g
1 M NaCl	5.84 g
100 mM EDTA (Na <sub>2</sub> •2H <sub>2</sub> O)	3.72 g

Solution B: To 30 ml of water; add 20 ml, 20 ml and 2 ml respectively of the Tris, NaCl and EDTA stock solutions; adjust to pH 7.4 with HCl and make up to 100 ml.

Solution C: Dilute Solution B with an equal volume of water.

## 2c. Protocol

1. Clarify the culture medium or the cell lysate by centrifugation at 3,700 g for 20 min at 4°C (see [Section 2d, Note 2](#)).
2. Using a swinging-bucket rotor concentrate and partially purify the virus by sedimentation through a 20% (w/v) iodixanol cushion (dilute Solution C with Solution D) at 67,000 g for 2.5 h (see [Section 2d, Note 3](#)).
3. During step 2 prepare two iodixanol solutions of 13% and 22% (w/v) by diluting Solution C with Solution D (see [Section 2d, Note 4](#)).
4. In tubes for the 13 ml swinging-bucket rotor use either a two-chamber gradient maker or a Gradient Master™ to prepare approx 12 ml continuous gradients from equal volumes the 13% and 22% iodixanol solutions (see [Section 2d, Note 4](#)).
5. Resuspend the virus pellet from step 2 in Solution D and apply approx 0.5 ml to each gradient.
6. Centrifuge the gradients at 250,000 g for 1.5 h. Use a slow deceleration program or turn off the brake during deceleration from 3000 rpm.
7. Collect the gradient by aspiration from the meniscus, upward displacement with a dense medium or tube puncture (for more information on harvesting gradients see [Application Sheet V04](#)) and analyze the fractions (see [Section 2d, Note 5](#)).

## 2d. Notes

1. Rift Valley virus was concentrated by ultrafiltration using a centrifugal filter device, rather than by sedimentation on to a dense cushion of iodixanol (see Step 2 in Protocol 2c). The virus was then purified on a 10-30% (w/v) iodixanol gradient [4,5]; the 10% and 30% iodixanol solutions should be prepared from OptiPrep™ using the same dilution procedure, with the same NaCl/EDTA/Tris solutions as described above. After forming the gradient in 14 ml tubes from equal volumes of the 10 and 30% iodixanol solutions, the gradient was top-loaded with the concentrated virus and the centrifugation was carried out at 210,000 g for 1.5 h at 4°C. The virus banded approx. half-way down the gradient.
2. Intracellular forms of the virus can be released by three rounds of freeze-thawing [2].
3. Novoa et al [2] pelleted the virus through a 30% (w/v) sucrose cushion; to maintain an isoosmotic environment for the virus, the 30% sucrose has been replaced by 20% (w/v) iodixanol. The ideal way of concentrating the virus is sedimentation on to a dense cushion of iodixanol, rather than pelleting. This however may be less convenient when, as in this case, the concentration of iodixanol in the viral suspension needs to be <13% (w/v) to permit loading on to the gradient. When recovering the band of virus as little as possible of the cushion must be aspirated. For more information on concentration of virus prior to purification see [Application Sheet V06](#).
4. Novoa et al [2] prepared nine solutions between 13% and 22% iodixanol (in 1% steps) and layered equal volumes (dense end first) in a centrifuge tube, snap-freezing each layer in dry ice before applying the next. The tubes were kept frozen until required and continuous gradients were formed by allowing the tubes to thaw at room temperature overnight. For more information on preparing continuous gradients see [Application Sheet V02](#).
5. Virus particles of increasing density can be harvested from the gradient: Type I has an annular structure (immature precursors); Type II is an intermediate dense form (these are both intracellular forms) and finally a dense extracellular form, distinguished morphologically from the Type II form [2].
6. Ariza et al [6] studied the nucleocapsid protein structure from Bunyamwera virus using the iodixanol gradient method of Novoa et al [2]. Working with Rift Valley fever virus Weingart et al [7] first concentrated the virus by pelleting through a 20% (w/v) iodixanol cushion (115,500 g for 1 h); then suspended the virus in a buffered saline (containing 1 mM EDTA) and then banded the virus in a discontinuous gradient of 10, 15, 20, 25 and 30% (w/v) iodixanol (210,000 g 1.5 hr).

### 3. Analysis of Hantavirus (self-generated gradient)

The protocol is adapted from refs 8-11 ([see also Section 3d, Notes 1 and 2](#)).

#### 3a. Solutions required

A. OptiPrep™

B. OptiPrep™ Diluent: Any suitable iso-osmotic balanced salt solution

#### 3b. Rotor requirements

Swinging-bucket rotor with approx. 13 ml tubes (e.g. Beckman SW41Ti)

Near-vertical rotor with approx. 5 ml tubes (e.g. Beckman NVT65.2)

#### 3c. Protocol

1. Dilute 5 vol. of OptiPrep™ with 1 vol. of Solution B to produce a 50% (w/v) iodixanol solution.
2. In tubes for the swinging-bucket rotor underlayer approx. 10 ml of the crude virus suspension with 2 ml of the 50% iodixanol solution using a syringe and metal cannula ([see Section 3d, Note 3](#)).
3. Centrifuge at approx 190,000 *g* for 3 h at 4°C.
4. Using a syringe and metal cannula collect 4 ml of liquid from the bottom of the tube i.e. the cushion + the banded virus + 2 ml of the balanced salt solution).
5. Mix the suspension with an extra 1 ml of the 50% iodixanol and transfer to an Optiseal™ for the near-vertical rotor ([see Section 3d, Notes 3-5](#)).
6. Centrifuge at approx 350,000 *g<sub>av</sub>* for 5 h and allow the rotor to decelerate from 2000 to 0 rpm using a controlled deceleration program (over at least 5 min) or turn off the brake at 2000 rpm.
7. Collect the gradient by tube puncture or any other chosen method; the virus will band in the bottom half of the gradient. For more information on harvesting gradients [see Application Sheet V04](#).

#### 3d. Notes

1. An alternative method in which the concentrated virus was layered over pre-formed continuous gradient formed by diffusion overnight at 4°C from 1.5 ml of 50%, 42%, 35%, 28%, 21%, 14% and 7% (w/v) iodixanol (OptiPrep™ diluted with HEPES-buffered 135 mM NaCl) centrifuged at 25,000 *g* for 15 h was devised by Huisken et al [12]. Although it may be acceptable to use a higher *g*-force for a shorter time, there is little doubt that the use of relatively low *g*-forces for longer times will provide the best resolution of any biological particles; moreover during the 15 h centrifugation the gradient will certainly become continuous and at the low speed of 25,000 *g* there will be little or no sedimentation of the iodixanol molecules themselves. A similar gradient was used by Li et al [13] at approx/ 110,000 *g* for 3 h.
2. More recently a 5-25% (w/v) iodixanol gradient was generated from a discontinuous one (5% step interval); after layering each step the gradient was frozen and after the final freezing the gradient was top-loaded with sample and centrifuged at 28,000 *g* for 1.5 h [14].
3. For larger volumes of virus use for example a Beckman SW28 for the virus concentration step and an NVT65 for the self-generated gradient and scale up all the volumes proportionately to fill the tubes. Although the larger volume swinging-bucket rotor cannot be run at 190,000 *g*, it is probably not necessary to increase the centrifugation time in step 3 to band the virus (although this should be checked out).
4. Vertical rotors of the same capacity are permissible and the gradient that is generated will be more or less identical, but a small cushion of 0.5 ml of OptiPrep™ should be included to stop any dense material from reaching the tube wall.
5. The final concentration of iodixanol is 30% (w/v).

#### 4. References

1. Palker, T.J. (1990) *Mapping of epitopes on human T-cell leukemia virus type 1 envelope glycoprotein* In: Human Retrovirology: HTLV (ed. Blattner, W.A.) Raven Press, NY, pp 435-445
2. Novoa, R.R., Calderita, G., Cabezas, P., Elliott, R.M. and Risco, C. (2005) *Key Golgi factors for structural and functional maturation of bunyamwera virus* J. Virol., **79**, 10852-10863
3. Cabezas, P. and Risco, C. (2006) *Studying cellular architecture in three dimensions with improved resolution: Ta replicas revisited* Cell Biol. Int., **30**, 747-754
4. Freiberg, A.N., Sherman, M.B., Morais, M.C., Holbrook, M.R. and Watowich, S.J. (2008) *Three-dimensional organization of Rift Valley fever virus revealed by cryoelectron tomography* J. Virol., **82**, 10341-10348
5. Wolf, M.C., Freiberg, A.N., Zhang, T., Akyol-Ataman, Z., Grock, A., Hong, P.W., Li, J., Watson, N.F., Fang, A.Q., Aguilar, H.C., Porotto, M., Honko, A.N., Damoiseaux, R., Miller, J.P., Woodson, S.E., Chantasirivisal, S., Fontanes, V., Negrete, O.A., Krogstad, P., Dasgupta, A., Moscona, A., Hensley, L.E., Whelan, S.P., Faull, K.F., Holbrook, M.R., Jung, M.E. and Lee, B. (2010) *A broad-spectrum antiviral targeting entry of enveloped viruses* Proc. Natl. Acad. Sci. USA, **107**, 3157–3162
6. Ariza, A., Tanner, S.J., Walter, C.T., Dent, K.C., Shepherd, D.A., Wu, W., Matthews, S.V., Hiscox, J.A., Green, T.J., Luo, M., Elliott, R.M., Fooks, A.R., Ashcroft, A.E., Stonehouse, N.J., Ranson, N.A., Barr, J.N. and Edwards, T.A. (2013) *Nucleocapsid protein structures from orthobunyaviruses reveal insight into ribonucleoprotein architecture and RNA polymerization* Nucleic Acids Res., **41**, 5912–5926
7. Weingart, H.M., Zhang, S., Marszal, P., McGreevy, A., Burton, L. and Wilson, W.C. (2014) *Rift valley fever virus incorporates the 78 kDa glycoprotein into virions matured in mosquito C6/36 cells* PLoS One, **9**: e87385.
8. Prescott, J.B., Hall, P.R., Bondu-Hawkins, V.S., Ye, C. and Hjelle, B. (2007) *Early innate immune responses to Sin Nombre Hantavirus occur independently of IFN regulatory factor 3, characterized pattern recognition receptors and viral entry* J. Immunol., **179**, 1796-1802
9. Bisoffi, M., Hjelle, B., Brown, D.C., Branch, D.W., Edwards, T.L., Brozik, S.M., Bondu-Hawkins, V.S. and Larson, R.S. (2008) *Detection of viral bioagents using a shear horizontal surface acoustic wave biosensor* Biosens. Bioelectron., **23**, 1397-1403
10. Hall, P.R., Hjelle, B., Brown, D.C., Ye, C., Bondu-Hawkins, V., Kilpatrick, K.A. and Larson, R.S. (2008) *Multivalent presentation of antihantavirus peptides on nanoparticles enhances infection blockade* Antimicrob. Agents Chemother., **52**, 2079-2088
11. Buranda, T., Wu, Y., Perez, D., Jett, S.D., Bondu-Hawkins, V., Ye, C., Edwards, B., Hall, P., Larson, R.S., Lopez, G.P., Sklar, L.A. and Hjelle, B. (2010) *Recognition of decay accelerating factor and avb3 by inactivated hantaviruses: Toward the development of high-throughput screening flow cytometry assays* Anal. Biochem., **402**, 151–160
12. Huiskonen, J.T., Hepojoki, J., Laurinmäki, P., Vaheri, A., Lankinen, H., Butcher, S.J. and Grünewald, K. (2010) *Electron cryotomography of Tula hantavirus suggests a unique assembly paradigm for enveloped viruses* J. Virol., **84**, 4889–4897
13. Li, S., Rissanen, I., Zeltina, A., Hepojoki, J., Raghwani, J., Harlos, K., Pybus, O.G., Huiskonen, J.T. and Bowden, T.A. (2016) *A molecular-level account of the antigenic hantaviral surface* Cell Rep., **15**, 959–967
14. Guo, Y., Wang, W., Sun, Y., Ma, C., Wang, X., Wang, X., Liu, P., Shen, S. et al (2016) *Crystal structure of the core region of hantavirus nucleocapsid protein reveals the mechanism for ribonucleoprotein complex formation* J. Virol., **90**, 1048-1061